Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis |
Go, Seong Woo
(Department of Internal Medicine, The Catholic University of Korea College of Medicine)
Kim, Boo Kyeong (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Lee, Sung Hak (Department of Pathology, The Catholic University of Korea College of Medicine) Kim, Tae-Jung (Department of Pathology, The Catholic University of Korea College of Medicine) Huh, Joo Yeon (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Lee, Jong Min (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Hah, Jick Hwan (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Kim, Dong Whi (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Cho, Min Jung (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Kim, Tae Wan (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Kang, Ji Young (Department of Internal Medicine, The Catholic University of Korea College of Medicine) |
1 | Delomas T, Darne C, Besson C. Lack of recurrence of imatinib- induced interstitial lung disease with nilotinib. Leuk Lymphoma 2012;53:332-3. DOI ScienceOn |
2 | Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56. |
3 | Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-4. DOI ScienceOn |
4 | Kim TH, Kim BG, Cho SW, Cho SK, Kim HJ, Yuh YJ, et al. Imatinib- mesylate induced interstitial pneumonitis in two CML patients. Tuberc Respir Dis 2011;71:210-5. DOI ScienceOn |
5 | Lee JW, Kim HJ, Kim KJ, Shin KC, Hong YH, Chung JH, et al. A case of imatinib-mesylate associated hypersensitivity pneumonitis. Tuberc Respir Dis 2005;59:423-6. DOI |
6 | Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011;6:235-43. DOI |
7 | Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004;18:645-6. DOI ScienceOn |
8 | Snyder LS, Hertz MI, Peterson MS, Harmon KR, Marinelli WA, Henke CA, et al. Acute lung injury: pathogenesis of intraalveolar fibrosis. J Clin Invest 1991;88:663-73. DOI |
9 | Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-59. DOI ScienceOn |
10 | Seki N, Ito A, Watanabe K, Shibakuki R, Seto T, Uematsu K, et al. Irreversible imatinib-induced pneumonitis following longterm imatinib administration. Intern Med 2007;46:1941-2. DOI ScienceOn |
11 | Walsh J, Absher M, Kelley J. Variable expression of plateletderived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol 1993;9:637-44. DOI ScienceOn |
![]() |